RPG Life Sciences Ltd

RPG Life Sciences Ltd

₹ 2,153 0.46%
21 May 12:29 p.m.
About

Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients[1]

Key Points

Business Overview:[1]
RPGLS is a part of the RPG Group. It started as a joint venture with G.D Searle and was renamed when G.D Searle withdrew its India operations. Currently, the group has major listed companies like KEC International, CEAT, Zensar Tech, etc.
RPGLS is an integrated research based pharmaceutical company operating in domestic and international markets in branded formulations, global generics and APIs

  • Market Cap 3,561 Cr.
  • Current Price 2,153
  • High / Low 2,977 / 1,381
  • Stock P/E 30.1
  • Book Value 321
  • Dividend Yield 0.74 %
  • ROCE 33.3 %
  • ROE 26.1 %
  • Face Value 8.00

Pros

  • Company is almost debt free.
  • Company has delivered good profit growth of 29.1% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 25.4%
  • Company has been maintaining a healthy dividend payout of 27.1%

Cons

  • The company has delivered a poor sales growth of 11.7% over past five years.
  • Earnings include an other income of Rs.95.3 Cr.
  • Debtor days have increased from 35.3 to 48.5 days.
  • Working capital days have increased from 57.7 days to 115 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
104 129 135 131 118 148 154 154 127 165 172 173 143
90 101 105 101 103 116 116 116 106 126 126 124 118
Operating Profit 14 28 30 29 16 32 37 38 21 39 46 49 25
OPM % 13% 22% 22% 22% 13% 22% 24% 25% 16% 24% 27% 28% 18%
1 1 1 1 2 2 2 2 2 2 -25 3 115
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 4 4 4 4 4 4 4 4 4 5 5 5 5
Profit before tax 11 25 27 26 14 30 35 36 18 36 15 47 135
Tax % 31% 28% 26% 26% 25% 26% 26% 26% 25% 26% 72% 26% 13%
8 18 20 19 10 22 26 26 13 27 4 35 117
EPS in Rs 4.55 11.01 12.07 11.55 6.26 13.36 15.64 16.00 8.01 16.18 2.54 21.12 70.95
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
236 242 279 294 344 330 376 389 440 513 582 653
224 228 256 274 306 296 315 318 353 408 453 494
Operating Profit 12 14 23 20 38 34 60 71 87 104 129 160
OPM % 5% 6% 8% 7% 11% 10% 16% 18% 20% 20% 22% 24%
66 1 1 18 1 1 -5 1 3 4 7 95
Interest 3 3 2 4 5 5 3 2 1 1 1 1
Depreciation 11 11 10 11 14 15 16 16 16 16 17 21
Profit before tax 65 1 12 23 20 15 36 54 73 92 118 233
Tax % 18% 0% 0% 10% 34% 28% 20% 25% 30% 26% 26% 21%
53 1 12 21 13 11 29 40 51 68 88 183
EPS in Rs 32.29 0.60 7.03 12.70 8.13 6.54 17.54 24.19 31.13 40.90 53.00 110.79
Dividend Payout % 6% 132% 23% 22% 30% 37% 23% 30% 31% 29% 30% 22%
Compounded Sales Growth
10 Years: 10%
5 Years: 12%
3 Years: 14%
TTM: 12%
Compounded Profit Growth
10 Years: 63%
5 Years: 29%
3 Years: 32%
TTM: 36%
Stock Price CAGR
10 Years: 30%
5 Years: 54%
3 Years: 61%
1 Year: 45%
Return on Equity
10 Years: 20%
5 Years: 24%
3 Years: 25%
Last Year: 26%

Balance Sheet

Figures in Rs. Crores

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 13 13 13 13 13 13 13 13 13 13 13 13
Reserves 113 112 120 134 142 147 163 203 243 294 362 517
15 33 23 45 54 36 12 2 1 0 0 0
56 39 49 55 82 54 78 85 88 112 138 127
Total Liabilities 196 197 205 247 291 251 267 303 345 419 513 658
106 105 109 137 131 128 123 113 104 124 114 184
CWIP 1 1 2 2 9 17 10 12 31 25 96 4
Investments 0 0 0 0 0 0 0 0 0 58 91 127
89 92 94 108 152 106 134 178 210 211 212 343
Total Assets 196 197 205 247 291 251 267 303 345 419 513 658

Cash Flows

Figures in Rs. Crores

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
-6 -2 33 7 15 46 50 58 65 91 94 78
59 -10 -15 -30 -16 -19 -11 -8 -35 -106 -79 -42
-54 12 -18 23 0 -26 -39 -10 -14 -17 -20 -27
Net Cash Flow 0 -0 -0 1 -1 0 0 40 17 -32 -5 9

Ratios

Figures in Rs. Crores

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 56 61 48 49 72 43 62 54 27 27 31 48
Inventory Days 180 149 156 163 171 136 133 162 214 203 200 159
Days Payable 176 109 135 102 165 83 127 132 117 138 140 135
Cash Conversion Cycle 60 101 70 110 78 96 68 84 124 91 90 72
Working Capital Days 51 76 54 50 62 53 46 53 47 33 25 115
ROCE % 2% 2% 9% 10% 13% 10% 23% 27% 31% 33% 35% 33%

Shareholding Pattern

Numbers in percentages

4 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
72.41% 72.62% 72.62% 72.82% 72.82% 72.82% 72.82% 72.82% 72.82% 72.82% 72.95% 72.95%
0.15% 0.08% 0.25% 0.38% 0.33% 0.46% 0.56% 0.90% 1.15% 1.35% 1.30% 1.46%
0.01% 0.03% 0.01% 0.11% 0.27% 1.57% 1.77% 2.16% 2.61% 5.45% 6.06% 6.14%
27.43% 27.27% 27.11% 26.70% 26.58% 25.15% 24.85% 24.12% 23.44% 20.40% 19.70% 19.46%
No. of Shareholders 22,11520,75721,36020,83720,22621,08821,86622,13722,23223,48124,89124,867

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls